Pfizer withdraws Macugen for DMO in Europe

The original victim of Lucentis' (ranibizumab) efficacy, Pfizer's Macugen, has been officially withdrawn from development in diabetic macular oedema, months after Pfizer handed back another DMO project. The move calls into question not only Pfizer's position in the indication, but also the prospects for a range of other compounds in development for DMO (Table 1)

The original victim of Lucentis' (ranibizumab) efficacy, Pfizer's Macugen, has been officially withdrawn from development in diabetic macular oedema, months after Pfizer handed back another DMO project. The move calls into question not only Pfizer's position in the indication, but also the prospects for a range of other compounds in development for DMO (Table 1)

The European Medicines Agency says it has been formally notified by Pfizer that it is withdrawing its application for an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By 

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

More from Therapeutic Category

Bristol Myers Shifts Five Drugs To Bain-Partnered Immunology Venture

 
• By 

Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.